711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I
0 activities
Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
1 activities
Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study
1 activities
Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study
Comparison of Cryopreserved Versus Non-Cryopreserved Strategies for Autologous Stemcell Transplantation in Multiple Myeloma in Two Centers in Uruguay
1 activities
Comparison of Cryopreserved Versus Non-Cryopreserved Strategies for Autologous Stemcell Transplantation in Multiple Myeloma in Two Centers in Uruguay
Eltrombopag Plus G-CSF for Peripheral Blood Stem Cell Mobilization: Interim Analysis of a Single Arm, Phase 2 Trial
1 activities
Eltrombopag Plus G-CSF for Peripheral Blood Stem Cell Mobilization: Interim Analysis of a Single Arm, Phase 2 Trial
Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors
1 activities
Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors
Safety and Efficacy of Etoposide Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma
1 activities
Safety and Efficacy of Etoposide Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma
Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
1 activities
Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
The Impact of Stem Cell Mobilization Regimen on Outcomes after Autologous Transplant for Multiple Myeloma
1 activities
The Impact of Stem Cell Mobilization Regimen on Outcomes after Autologous Transplant for Multiple Myeloma